肺鳞癌合并糖尿病中西医结合临床治疗分析  

Analysis of Clinical Treatment of Lung Squamous Cell Carcinoma with Diabetes by Integrated Traditional Chinese and Western Medicine

作　　者：陈鍱 CHEN Ye(Department of Oncology,Chaozhou Central Hospital,Chaozhou,Guangdong Province,521000 China)

机构地区：[1]潮州市中心医院肿瘤科,广东潮州521000

出　　处：《糖尿病新世界》2021年第10期47-50,共4页Diabetes New World Magazine

摘　　要：目的浅析在肺鳞癌合并2型糖尿病患者的治疗中,应用中西医结合治法的临床可行性。方法回顾性分析该院2015年1月—2020年12月因肺鳞癌合并2型糖尿病入院接受药物治疗的80例患者作为研究样本,基于药物治疗方案差异进行分组,其中40例接受单一西医化疗(对照组),另40例在化疗基础上加用中药丸剂治疗(研究组)。比较两组空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、肺癌近期疗效、肺癌远期疗效、控糖疗效、白细胞分化抗原CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)、不良反应、生存质量改善率差异。结果两组治疗前的FPG、2 hPG、HbA1c、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平比较,差异无统计学意义(P>0.05);治疗后,研究组FPG、2 hPG、HbA1c水平低于对照组,CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,差异有统计学意义(P<0.05);两组治疗后的CD8^(+)水平比较,差异无统计学意义(P>0.05)。两组不良反应比较(17.50%vs 15.00%),差异无统计学意义(P>0.05);研究组近期治疗有效率(92.50%)高于对照组(65.00%),PFS长于对照组,1年生存率(95.00%)高于对照组(72.50%),生存质量改善率(95.00%)高于对照组(82.50%),差异有统计学意义(P<0.05)。结论在肺鳞癌合并糖尿病患者的治疗中,应用中西医结合治法,可有效控制患者血糖值,提升免疫力,改善近期疗效与远期预后结局,提升患者病期生存质量,应用安全性高,值得关注。Objective To analyze the clinical feasibility of applying integrated traditional Chinese and western medicine in the treatment of patients with lung squamous cell carcinoma with type 2 diabetes.Methods A retrospective analysis of 80 patients with lung squamous cell carcinoma combined with type 2 diabetes who were admitted to the hospital for medical treatment between January 2015 and December 2020 was used as the research sample.The patients were divided into groups based on the difference of the drug treatment plan.Among them,40 patients received a single Western medicine chemotherapy(control group),the other 40 cases were treated with traditional Chinese medicine pills on the basis of chemotherapy(study group).Compared the two groups of fasting blood glucose(FPG),2 h blood glucose after meal(2 hPG),glycosylated hemoglobin(HbA1c),short-term effects of lung cancer,the long-term efficacy of lung cancer,the efficacy of glucose control,leukocyte differentiation antigen CD4^(+),CD8^(+),CD4^(+)/CD8^(+),adverse reactions,and differences in the improvement rate of quality of life.Results There was no statistically significant difference in the FPG,2 hPG,HbA1c,CD4^(+),CD8^(+),CD4^(+)/CD8^(+) levels between the two groups before treatment(P>0.05);after treatment,the FPG,2 hPG,and HbA1c levels in the study group were lower than those in the control group,and CD4^(+)The CD4^(+)/CD8^(+) level was higher than that of the control group,and the difference was statistically significant(P<0.05);the comparison of the CD8^(+) levels between the two groups after treatment was not statistically significant(P>0.05).Comparison of adverse reactions between the two groups(17.50%vs 15.00%),the difference was not statistically significant(P>0.05);the recent treatment effective rate of the study group(92.50%)was higher than that of the control group(65.00%),PFS was longer than the control group,1 year survival rate(95.00%)was higher than that of the control group(72.50%),and the improvement rate of quality of life(95.00%)was higher than tha

关 键 词：肺鳞癌 糖尿病 中西医结合 化疗 消渴丸 

分 类 号：R734.2[医药卫生—肿瘤]